MoonLake Immunotherapeutics
Status: Publicly traded
Direct answer
MoonLake Immunotherapeutics is publicly traded on NASDAQ under the ticker MLTX.
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of...
Can you invest in MoonLake Immunotherapeutics?
Yes. MoonLake Immunotherapeutics is publicly traded on NASDAQ under the ticker MLTX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for MoonLake Immunotherapeutics
Detailed equity research is provided by MarketSnap.